| Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease JJM Van Dongen, EA Macintyre, JA Gabert, E Delabesse, V Rossi, ... Leukemia 13 (12), 1901-1928, 1999 | 1537 | 1999 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 884 | 2018 |
| Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ... New England Journal of Medicine 383 (10), 931-943, 2020 | 678 | 2020 |
| High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial E Thiel, A Korfel, P Martus, L Kanz, F Griesinger, M Rauch, A Röth, ... The lancet oncology 11 (11), 1036-1047, 2010 | 668 | 2010 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 648 | 2017 |
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study L Crinò, E Dansin, P Garrido, F Griesinger, J Laskin, N Pavlakis, ... The lancet oncology 11 (8), 733-740, 2010 | 380 | 2010 |
| Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML S Schnittger, U Kinkelin, C Schoch, A Heinecke, D Haase, T Haferlach, ... Leukemia 14 (5), 796-804, 2000 | 355 | 2000 |
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study S Novello, J Mazières, IJ Oh, J De Castro, MR Migliorino, Å Helland, ... Annals of Oncology 29 (6), 1409-1416, 2018 | 314 | 2018 |
| Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia R Schroers, F Griesinger, L Trümper, D Haase, B Kulle, L Klein-Hitpass, ... Leukemia 19 (5), 750-758, 2005 | 310 | 2005 |
| Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Clinical Oncology 38 (31), 3592-3603, 2020 | 298 | 2020 |
| FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance CM Zwaan, S Meshinchi, JP Radich, AJP Veerman, DR Huismans, ... Blood 102 (7), 2387-2394, 2003 | 290 | 2003 |
| The MLL recombinome of acute leukemias C Meyer, B Schneider, S Jakob, S Strehl, A Attarbaschi, S Schnittger, ... Leukemia 20 (5), 777-784, 2006 | 283 | 2006 |
| Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Thoracic Oncology 16 (12), 2091-2108, 2021 | 234 | 2021 |
| Prevention, diagnosis, therapy, and follow-up of lung cancer G Goeckenjan, H Sitter, M Thomas, D Branscheid, M Flentje, F Griesinger, ... Pneumologie 65 (01), 39-59, 2011 | 232 | 2011 |
| PubMed results G Goeckenjan, H Sitter, M Thomas, D Branscheid, M Flentje, F Griesinger, ... Pneumologie 65 (8), e51-e75, 2011 | 216 | 2011 |
| Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia RF Schlenk, S Fröhling, F Hartmann, JT Fischer, A Glasmacher, ... Leukemia 18 (11), 1798-1803, 2004 | 215 | 2004 |
| Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO … E Fokas, A Schlenska-Lange, B Polat, G Klautke, GG Grabenbauer, ... JAMA oncology 8 (1), e215445-e215445, 2022 | 187 | 2022 |
| A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia F Griesinger, H Hennig, F Hillmer, M Podleschny, R Steffens, A Pies, ... Genes, Chromosomes and Cancer 44 (3), 329-333, 2005 | 180 | 2005 |
| Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group C Langebrake, U Creutzig, M Dworzak, O Hrusak, E Mejstrikova, ... Journal of Clinical Oncology 24 (22), 3686-3692, 2006 | 170 | 2006 |
| Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients … A Papachristofilou, MM Hipp, U Klinkhardt, M Früh, M Sebastian, C Weiss, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 154 | 2019 |
